The ESMO Congress is a highly influential oncology platform for clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from all over the world. VJOncology will be attending the European Society for Medical Oncology (ESMO) 2023 Congress which will be held in Madrid, Spain between 20th - 24th October 2023. Leading experts in oncology will present face-to-face on the latest developments across the field, including updates in key trials as well as debates on burning topics in the field of medical oncology. Stay tuned for the latest coverage of ESMO 2023 with VJOncology where we will be live in Madrid!
View all videos

ESMO 2023

20–24 October 2023 | Madrid, Spain
VJOncology avatar; VJ Oncology @VJOncology ·
November 30, 2023 1730149756704379293

🚨 24 hours until #ESMOAsia23 🚨

Make sure to stay tuned for the congress – follow us @VJOncology and head to http://VJOncology.com for exciting developments

@myESMO #Oncology #ImmunoOnc

Image for the Tweet beginning: 🚨 24 hours until #ESMOAsia23 Twitter feed image.
Reply on Twitter 1730149756704379293 Retweet on Twitter 1730149756704379293 1 Like on Twitter 1730149756704379293 3 Twitter 1730149756704379293
VJOncology avatar; VJ Oncology @VJOncology ·
November 29, 2023 1729798665982603370

November is #LungCancer Awareness month 🫁 📣

Check out this NEW VJSessions episode: #CTscreening for patients with #lungcancer in the UK with @BTOGORG 💬 🇬🇧

With David Baldwin, Beth Sage, Phillip Crosbie, Matthew Callister and Arjun Nair ⬇️

https://ow.ly/yozx50Q5n7H

#LCsm

Image for the Tweet beginning: November is #LungCancer Awareness month Twitter feed image.
Reply on Twitter 1729798665982603370 Retweet on Twitter 1729798665982603370 3 Like on Twitter 1729798665982603370 2 Twitter 1729798665982603370
Load More

ESMO 2023

20–24 October 2023 | Madrid, Spain
  The ESMO Congress is a highly influential oncology platform for clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from all over the world. VJOncology will be attending the European Society for Medical Oncology (ESMO) 2023 Congress which will be held in Madrid, Spain between 20th - 24th October 2023. Leading experts in oncology will present face-to-face on the latest developments across the field, including updates in key trials as well as debates on burning topics in the field of medical oncology. Stay tuned for the latest coverage of ESMO 2023 with VJOncology where we will be live in Madrid!
View all videos
VJOncology avatar; VJ Oncology @VJOncology ·
November 30, 2023 1730149756704379293

🚨 24 hours until #ESMOAsia23 🚨

Make sure to stay tuned for the congress – follow us @VJOncology and head to http://VJOncology.com for exciting developments

@myESMO #Oncology #ImmunoOnc

Image for the Tweet beginning: 🚨 24 hours until #ESMOAsia23 Twitter feed image.
Reply on Twitter 1730149756704379293 Retweet on Twitter 1730149756704379293 1 Like on Twitter 1730149756704379293 3 Twitter 1730149756704379293
VJOncology avatar; VJ Oncology @VJOncology ·
November 29, 2023 1729798665982603370

November is #LungCancer Awareness month 🫁 📣

Check out this NEW VJSessions episode: #CTscreening for patients with #lungcancer in the UK with @BTOGORG 💬 🇬🇧

With David Baldwin, Beth Sage, Phillip Crosbie, Matthew Callister and Arjun Nair ⬇️

https://ow.ly/yozx50Q5n7H

#LCsm

Image for the Tweet beginning: November is #LungCancer Awareness month Twitter feed image.
Reply on Twitter 1729798665982603370 Retweet on Twitter 1729798665982603370 3 Like on Twitter 1729798665982603370 2 Twitter 1729798665982603370
Load More

Watch all videos from ESMO 2023!

View all
0:54
NIBIT-M2: 7-year outcomes and QoL analysis in melanoma patients
Georgina V. Long • 21 Oct 2023
1:42
SECOMBIT: treatment sequencing in metastatic melanoma and incidence of brain metastasis
Georgina V. Long • 21 Oct 2023
3:37
Phase III THOR study: erdafitinib vs. pembrolizumab in FGFR-altered advanced or metastatic UC
Arlene O. Siefker-Radtke • 20 Oct 2023
3:48
AdvanTIG-202: tislelizumab ± ociperlimab in recurrent/metastatic cervical cancer
Jung-Yun Lee • 21 Oct 2023

GU at ESMO 2023!

View all
3:37
Phase III THOR study: erdafitinib vs. pembrolizumab in FGFR-altered advanced or metastatic UC
Arlene O. Siefker-Radtke • 20 Oct 2023
2:48
LITESPARK-005: Belzutifan versus everolimus in ccRCC
Laurence Albiges • 21 Oct 2023
3:38
Breakthroughs in urothelial cancer treatment at ESMO 2023
Joaquim Bellmunt • 22 Oct 2023
5:44
DAD: sacituzumab govetican + enfortumab vedotin as a 2L therapy for mUC
Bradley A. McGregor • 22 Oct 2023

Lung cancer at ESMO 2023!

View all
3:17
Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC
Byoung Chul Cho • 21 Oct 2023
1:56
eNRGy: zenocutuzumab in NRG1 fusion-positive NSCLC
Alison Schram • 21 Oct 2023
0:34
Rational for HER3-targeting in NRG1 fusion-positive NSCLC
Alison Schram • 21 Oct 2023
2:04
MARIPOSA-2: amivantamab + chemo (± lazertinib) vs chemo in EGFR-mutated NSCLC post-osimertinib
Antonio Passaro • 22 Oct 2023

Check out some of the experts who we will be interviewing this year!

Paolo Ascierto
MD
National Tumor Institute Fondazione G. Pascale, Naples, Italy
Erika Hamilton
MD
Sarah Cannon Cancer Center, Nashville, TN
Hope Rugo
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Joaquim Bellmunt
Dana Farber Cancer Institute, Boston, MA
Laurence Albiges
MD, PhD
Gustave Roussy, Paris, France
Sara Tolaney
MD, MPH
Dana Farber Cancer Institute, Boston, MA
Peter Schmid
FRCP, MD, PhD
Barts Cancer Institute, London, UK
Enrique Grande
MD, PhD
MD Anderson Cancer Center Madrid, Madrid, Spain
Georgina Long
BSc, PhD, MBBS, FRACP, FAHMS
The University of Sydney, North Sydney, Australia
Arlene Siefker-Radtke
MD
University of Texas, MD Anderson Cancer Center, Houston, TX
The content of VJOncology is intended for healthcare professionals